Markus Weiß

Execute external growth opportunities to reshape portfolio and to support the Innovation/Development activities globally and across assigned categories. Pursue a broad range of deal structures to support the strategic intent of the partnership including in- and out-licensing activities, commercial deals incl. distribution agreements, M&A, alternative models such as joint ventures, commercial collaborations and other types of strategic alliance.

Accountable for the implementation of the Emerging Markets Strategy across the Emerging Market (EM) region in line with the agreed prioritization of initiatives. Responsible to develop and manage the detailed implementation plan and align with Heads on the strategic opportunities and priorities. Responsible for the co-ordination and management of the overall implementation process. Responsible for the future development and implementation of additional strategies.

Explores new product ideas for the pain category and contributes to the identification of business opportunities. Builds a sustainable pipeline of new product opportunities via in-licensing, co-operations, global and local acquisitions, starts external or internal developments. Key markets: Japan, Germany, Russia, France, Brazil, Mexico, LatAM and Turkey. Responsible for the regional BD&L activities in the LatAM region incl. Brazil and Mexico to drive licensing, switch and M&A activities.

Develops Corporate CHC Strategy together with Management team. Enables local implementation and assures continuous profit/productivity improvement. Leads financial Target setting for region. Implement Portfolio Management of International Core Brands. Conducts MAG with local M&S responsible. Steers professional succession planning for key positions in respective countries (Italy, France, Spain, Greece and Portugal => EUR 200 Mil. sales responsibility).

Ensure the implementation of the defined CHC Corporate strategy in Germany, Spain, Russia, Poland, CEE, Greece and contribute to the achievement of the agreed regional business goals and the strategic business plan for Europe. Assist the Head of CDept CHC Europe in preparing the tactical business plans for the countries assigned and ensure and monitor the implementation of the defined strategies for the Flagships and International Brands with CDept CHC marketing.

Achievements: Mucosolvan® grew from EUR 107 Mil. to EUR 134 Mil. sales; key markets: China, Korea, Germany, France, Italy, Russia, Spain, Brazil and Mexico. Lead successful implementation of the Mucosolvan® brand strategies and lifecycle projects in the Americas, Asia and Europe to develop the cough and cold franchise and contribute to the delivery of the strategic objectives for the Consumer Healthcare business.

Achievements: Dulcolax® grew from EUR 100 Mil. to EUR 111 Mil. sales by increasing profitability in this period and strengthened its world-wide # 1 position. Increased the level and quality of innovation, built and protected the integrity of the Dulcolax® brand equity and shared best practices for the brand in order to increase profitable top and bottom line growth. Drove consumer communication strategies across geographic markets and built brand long-term global strategic directions.

Developed customized marketing plans for German pharmaceutical companies on their entry into the U.S. market for over-the-counter goods. Implemented strategic plans for distribution of pharmaceutical products in various distribution channels.

Researched U.S. market to target potential domestic distribution/sales partners for clients’ products, in regional and national markets. Supported business development of newly formed German-U.S. joint ventures for distribution of over-the-counter and homeopathic products.

Created marketing strategies for new products including cough and cold remedies, analgesics e.g. Dolormin® and dietary supplements. Developed creative approaches to increasing targeted market shares of established brands. Responsible for developing an interactive web site for the company’s expansion into the Internet and its launching of strategic brand sites for its focus products such as Imodium® and Nizoral®, in cooperation with the international franchise team in the U.S.